The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 8, Pages e106221
Publisher
Public Library of Science (PLoS)
Online
2014-08-30
DOI
10.1371/journal.pone.0106221
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study
- (2013) Aoife G. Cotter et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents
- (2012) Roger Bedimo et al. AIDS
- Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
- (2012) Emanuele Focà et al. BMC INFECTIOUS DISEASES
- A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results
- (2012) Michael J. Kozal et al. HIV CLINICAL TRIALS
- Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)
- (2011) Babafemi Taiwo et al. AIDS
- Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week Results
- (2011) Jacques Reynes et al. HIV CLINICAL TRIALS
- Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202
- (2011) Grace A. McComsey et al. JOURNAL OF INFECTIOUS DISEASES
- A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206
- (2010) Marisa Tungsiripat et al. AIDS
- Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study
- (2010) Hans‐Jürgen Stellbrink et al. CLINICAL INFECTIOUS DISEASES
- Reduced bone mineral density in HIV-infected patients: prevalence and associated factors
- (2009) Charles Cazanave et al. AIDS
- Simplification of Antiretroviral Therapy with Tenofovir‐Emtricitabine or Abacavir‐Lamivudine: A Randomized, 96‐Week Trial
- (2009) Allison Martin et al. CLINICAL INFECTIOUS DISEASES
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
- (2009) Jeffrey L Lennox et al. LANCET
- Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy
- (2009) Paul E. Sax et al. NEW ENGLAND JOURNAL OF MEDICINE
- Class-Sparing Regimens for Initial Treatment of HIV-1 Infection
- (2008) Sharon A. Riddler et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search